Accessibility Menu
Idorsia logo

Idorsia(OTC) IDRSF

Market Cap$1.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-59%
5 Year-70%
1 Year+109%
1 Month-4%
$7.31
-5.68%
-0.44Today
Idorsia last closing stock price
MetricPriceDate
Last closeUSD 7.312026-08-20
Idorsia stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.68%USD 7.752026-08-13
1 month-3.82%USD 7.602026-07-21
3 month+27.13%USD 5.752026-05-20
Year to date+39.24%USD 5.252025-12-31
1 year+108.86%USD 3.502025-08-19
3 year+13.33%USD 6.452023-08-17
5 year-70.16%USD 24.502021-08-20
Since inception-59.39%USD 18.002017-07-17

Idorsia Financials at a Glance

Market Cap

$1.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 199.56M

Net Income (TTM)

-CHF 316.78M

EPS (TTM)

-$1.65

P/E Ratio

-4.43

Dividend

$0.00

Beta (Volatility)

-0.03 (Low)

Price

$7.31

Volume

302

Open

$7.31

Previous Close

$7.31

Daily Range

$7.31 - $7.31

52-Week Range

$3.30 - $8.19

Estimated Earnings Date

Oct 29, 2026

IDRSF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Idorsia

Idorsia Ltd is a biopharmaceutical company based in Allschwil, Switzerland, established in 2017. The company focuses on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs across various therapeutic areas.

Products and Services
  • Innovative medicines targeting CNS, cardiovascular, and immunological disorders
  • Collaboration with Janssen Biotech for aprocitentan and related products
  • Development of ACT-709478 for epilepsy in partnership with Neurocrine Biosciences
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Strategic alliances enhance market reach and development capabilities
  • Focus on rare diseases presents unique market opportunities
Financial Highlights
  • Q2 2026 revenue of 52.7 million CHF, showing consistent demand
  • Trailing twelve months (TTM) revenue of 227.5 million CHF, indicating growth potential
  • Operating loss reduced from 78 million CHF in Q4 2025 to 35.8 million CHF in Q2 2026
Idorsia Ltd is positioned in the biotechnology sector, focusing on unmet medical needs with a diverse pipeline. The company has established strategic partnerships that enhance its development capabilities and market access. Recent financial performance indicates a growing revenue stream, with a notable reduction in operating losses, suggesting improved operational efficiency. The focus on innovative treatments, particularly in rare diseases, positions Idorsia as a compelling option for investors interested in the biotechnology landscape.
AI Generated • Jul 31, 2026

Industry

Biotechnology

Sector

Health Care

Employees

487

CEO

Jean-Paul Clozel, MD

Website

www.idorsia.com

Headquarters

Allschwil, BL 4123, CH

IDRSF Financials

Key Financial Metrics (TTM)

Gross Margin

80.96%

Operating Margin

-121.76%

Net Income Margin

-158.28%

Return on Equity

27.25%

Return on Capital

-89.54%

Return on Assets

-68.19%

Earnings Yield

-22.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

265.12M

Volume

302

Avg. Volume

7.11K

Financials (TTM)

Gross Profit

CHF 157.43M

Operating Income

-CHF 159.25M

EBITDA

-CHF 181.95M

Operating Cash Flow

-CHF 124.88M

Capital Expenditure

-CHF 5.39M

Free Cash Flow

-CHF 130.27M

Cash & ST Invst.

CHF 88.69M

Total Debt

CHF 1.32B

Idorsia Performance Analysis

Idorsia annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 101,670,555163.0%
20232023-12-31CHF 169,571,80666.8%
20242024-12-31CHF 127,753,087-24.7%
20252025-12-31CHF 265,608,254107.9%
Idorsia sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-42.6%
Q42025-12-3115.9%
Q12026-03-3119.5%
Q22026-06-30-8.2%
Idorsia annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF -4.8918.6%
20232023-12-31CHF -1.86-61.9%
20242024-12-31CHF -1.64-11.7%
20252025-12-31CHF -0.63-61.8%
Idorsia sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-562.3%
Q42025-12-3120.0%
Q12026-03-3143.8%
Q22026-06-30-133.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CHF 52.70M

-27.0%

Gross Profit

CHF 37.91M

-44.9%

Gross Margin

71.94%

N/A

Market Cap

$1.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.98M

N/A

Employees

487

N/A

Net Income

-CHF 107.05M

-841.1%

EBITDA

-CHF 32.30M

-637.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CHF 88.69M

+7.9%

Total Debt

CHF 1.32B

+1.2%

Accounts Receivable

CHF 51.66M

-25.5%

Inventory

CHF 70.93M

+6.5%

Long Term Debt

CHF 1.06B

-2.7%

Short Term Debt

CHF 256.64M

+21.4%

Return on Assets

-68.19%

N/A

Return on Invested Capital

-3.07%

N/A

Free Cash Flow

-CHF 34.97M

+22.3%

Operating Cash Flow

-CHF 34.23M

+2.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BPMUFBasilea Pharmaceutica AG
$77.40+0.00%
WHTCFWELL Health Technologies Corp.
$3.26+2.81%
NNCSFNanosonics Limited
$2.30+0.00%
INRLFValneva SE
$3.45+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$41.20+0.06%
MSTRStrategy
$112.39+0.08%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.25-0.02%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$122.21+0.01%

Questions About IDRSF

What is the current price of Idorsia?

Idorsia is trading at $7.31 per share.

What is the 52-week range for Idorsia?

Over the past 52 weeks, Idorsia has traded between $3.30 and $8.19.

How much debt does Idorsia have?

As of the most recent reporting period, Idorsia reported total debt of CHF 1.66B.

How much cash does Idorsia have on hand?

Idorsia reported CHF 109.95M in cash and cash equivalents in its most recent financial results.

What is Idorsia’s dividend yield?

Idorsia does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services